Prota Therapeutics is an Australian, proprietary limited, privately-held biotech company established in 2016 to develop and commercialize novel oral immunotherapy treatments. Prota holds an exclusive license to the proprietary food immunotherapy technology, developed at the MCRI. Series A funding of AUD $15m was secured from OneVentures, a leading Australian venture capital investment firm (OneVentures’ Healthcare Fund III) – including $5M from the Australian Commonwealth Government Biomedical Translation Fund – as well as private investment. This has enabled Prota to advance it’s clinical program, develop scalable cGMP product manufacturing processes, and initiate discussions with regulatory agencies in the lead up to a planned large-scale pivotal Phase 3 efficacy and safety study for the PRT120 peanut allergy treatment.
Prota Therapeutics has its headquarters in Melbourne, Australia.
New York
545 West 25th Street, 20th Floor New York, NY, USA 10001
Singapore
79 Science Park Drive, Level 06 Unit 01/08, CINTECH IV, Science Park 1 Singapore 118264
Prota Therapeutics has its headquarters in Melbourne, Australia.
New York
545 West 25th Street, 20th Floor New York, NY, USA 10001
Singapore
79 Science Park Drive, Level 06 Unit 01/08, CINTECH IV, Science Park 1 Singapore 118264
Total raised: $21M
Investors 1
| Date | Name | Website |
| 11.01.2024 | SPRIM Glob... | sprim.net |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.01.2024 | - | $21M | SPRIM Glob... |
Mentions in press and media 9
| Date | Title | Description |
| 18.09.2024 | Just what the doctor ordered: 24 Aussie health tech startups that raised millions in 2024 | Some of the many Australian founders who have raised millions in funding this year. Source: SmartCompany. article-article-body There’s plenty to get excited about when it comes to health tech in Australia. From pioneering treatments for foo... |
| 29.04.2024 | Prota Therapeutics' CEO Mimi Tang honoured at BioMelbourne Network's Women in Leadership Awards 2024 | MELBOURNE, Australia, April 29, 2024 /PRNewswire/ -- Prota Therapeutics' CEO Professor Mimi Tang has been honoured in the prestigious 2024 BioMelbourne Network Women in Leadership Awards. Professor Tang's exceptional work as a lead research... |
| 26.04.2024 | Ten startup raises worth getting excited about in 2024 | Femtek founder and CEO Olivia Orchowski. Source: Supplied article-article-body At SmartCompany, we keep a close eye on the startups raising capital each week and it gives us a box-seat view of groundbreaking Australian innovations. While fu... |
| 18.01.2024 | Deals in brief: EDBI invests in AlphaSense, Blue Earth Capital secures USD 378 million for climate impact strategy, multiple China and India deals, and more | Singapore’s EDBI invests in AlphaSense’s Series E round AlphaSense, a market intelligence and search platform, has secured an undisclosed amount of strategic funding from Singapore-based investor EDBI. This investment is part of AlphaSense’... |
| 17.01.2024 | Deals in brief: Meals In Minutes, Meiro, and Prota Therapeutics secure funding, ABC Impact reaches first close of second fund, multiple China and India deals, and more | Meals In Minutes secures USD 1.5 million in 500 Global-led round Meals In Minutes, a Malaysia-based startup exploring an advanced meal kit concept, has secured USD 1.5 million in a seed funding round led by 500 Global with the support of an... |
| 17.01.2024 | Prota Therapeutics Raises US $21M in Equity and Debt Financing | Prota Therapeutics, a Melbourne, Australia-based biotechnology company focused on the development of novel oral immunotherapy treatments that induce remission of allergy, raised US$21M in equity and debt funding. The round was led by SPRIM ... |
| 16.01.2024 | Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments | Financing advances development of Prota’s peanut allergy remission therapy in preparation for a Phase 3 clinical trial Source: Prota Therapeutics Sectors: BioTech |
| 09.02.2022 | Prota Therapeutics Achieves Peanut Allergy Treatment Milestone: Groundbreaking Clinical Trial Data Demonstrates Clinical Remission of Peanut Allergy in Paediatric Patients | Groundbreaking New Clinical Trial Data Published in The Lancet Child & Adolescent Health Data shows that 51% of participants achieved sustained unresponsiveness (clinical remission) to peanut after 18 months of treatment Prota Therapeut... |
| - | Prota Therapeutics | “Prota Therapeutics | Developing a novel approach to allergen immunotherapy” |